Mr. Christopher Moreau reports

ALGERNON ANNOUNCES INCREASE TO PRIVATE PLACEMENT FINANCING TO $750,000 AND CLOSE OF THIRD TRANCHE

Algernon Health Inc. has increased its non-brokered private placement financing, previously announced on Nov. 6, 2025, to $750,000 and has closed the third tranche. Gross proceeds from the third tranche totalled $352,500 from the sale of 5,035,714 units at an issue price of seven cents per unit. The closing of the third tranche brings the financing to a total of $739,500 from the sale of 10,564,286 units, including the closing of the first and second tranches on Nov. 14, 2025, and Nov. 28, 2025, respectively.

The company did not pay any cash finders' fees pertaining to the third tranche of the offering.

The company will use the proceeds of the offering toward advancing its Alzheimer's disease program, including the opening of its first U.S. AD clinic, general and administrative expenses, and working capital purposes.

The securities issued and issuable, described in this and the previous news release on Nov. 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

About Algernon Health Inc.

Algernon Health is a Canadian health care company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease, as well as other forms of dementia, epilepsy, neuro-oncology and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC that will oversee all U.S. neuroimaging operations.

We seek Safe Harbor.